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A monoclonal antibody L8 specific to fibronectin was shown to inhibit fibronectin incorporation into the 
fibroblast extracellular matrix. Antibody L8 could not interact with fibronectin complexed with gelatin. The 
results suggest he existence of a specific site on the fibronectin molecule playing a critical role in the assem- 
bly of the fibronectin extracellular matrix. This site is located near the collagen-binding domain. 
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1. INTRODUCTION 
Fibronectin is an adhesive glycoprotein present 
in a soluble form in plasma and in an insoluble 
form in connective tissues and in association with 
basement membranes [l-3]. Fibronectin in cell 
cultures is secreted into the medium or deposited 
into the extracellular matrix and on the cell sur- 
face. The cell surface and extracellular fibronectin 
is found in close association with collagens, pro- 
teoglycans and other components of the ex- 
tracellular matrix [4,5]. Plasma fibronectin can be 
incorporated into extracellular matrices of dif- 
ferent tissues and cultured cells [6-91. It was pro- 
posed that a special receptor on substrate-attached 
cells is involved in assembly of soluble fibronectin 
into insoluble fibrils of the extracellular matrix [8]. 
Fibronectin matrix formation may also occur 
through a self-assembly process [9]. In both cases 
the amino-terminal part of fibronectin was respon- 
sible for incorporation of plasma fibronectin into 
the extracellular matrix [9,10]. To learn more 
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about assembly of the fibronectin matrix we have 
studied the effect of monoclonal antibody to 
fibronectin on the formation of fibroblast ex- 
tracellular matrix. Antibody L8 was shown to be 
able to prevent extracellular fibronectin fibril for- 
mation. Our results suggest the existence of a func- 
tional site on fibronectin which is required for 
assembly of soluble fibronectin into insoluble ex- 
tracellular matrix. 
2. MATERIALS AND METHODS 
Monoclonal antibody L8 was established after 
immunization of BALB/C mice with rat aorta 
smooth muscle cells [ 111. Positive clones secreting 
antifibronectin antibodies were expanded as ascites 
tumors in BALB/C mice. For the experiments the 
IgG fraction was isolated from ascites fluid by 
chromatography on DEAE-cellulose. The obtain- 
ed monoclonal antibody had a purity greater than 
98% according to polyacrylamide gel elec- 
trophoresis. 
Human skin fibroblasts were grown on glass 
coverslips in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 0.1 mg/ml of different 
monoclonal antibodies or preimmune IgG, 10% 
fetal calf serum depleted of fibronectin, and 1 
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Fig. 1. Interaction of monoclonal antibodies L8 with human plasma fibronectin. (A) Polystyrene plates were coated with 
native fibronectin (A---A); bovine serum albumin (M); prior to coating fibronectin was incubated in PBS, 
containing 6 M urea (M); prior to coating fibronectin was incubated in PBS containing 0.02 M dithiothreitol 
(ti). (B) Polystyrene plates were coated with gelatin (o--o,o---o) or bovine serum albumin (&---A) and 
fibronectin was allowed to bind to gelatin and albumin. After washing monoclonal antibody L8 (M) or other 
monoclonal antibodies (W, ti) were added into the wells. Rabbit (anti-mouse IgG) IgG conjugated with 
peroxidase were used to detect monoclonal antibody bound to immobilized fibronectin-gelatin complex. 
week after plating the deposition of extracellular 
matrix fibronectin was detected by im- 
munofluorescence. For immunostaining the 
coverslips were fixed with 5% paraformaldehyde 
for 20 min and washed in phosphate-buffered 
saline, pH 7.4 (PBS). After a wash in PBS samples 
were incubated for 1 h in the PBS containing 
affinity-purified rabbit polyclonal antibodies to 
human plasma fibronectin (0.02 mg/ml). The 
samples were then incubated for 1 h in solution 
containing fluorescein-conjugated goat anti-rabbit 
IgG, 0.05 mg/ml, followed by several washes in 
PBS. The cells were mounted in 50% glycerol/PBS 
and viewed with Zeiss photomicroscope III equip- 
ped with phase contrast and epifluorescence. 
Interaction of monoclonal antibody L8 with 
fibronectin was tested by enzyme-linked im- 
munoassay [ 121. Microtitration plates were coated 
with proteins (0.01 mg/ml). Unbound protein was 
washed out and monoclonal antibody in PBS con- 
taining 0.05% Tween 20 was added. Antibodies 
were allowed to interact with protein coating the 
plate for 60 min at 20°C. Rabbit (anti-mouse IgG) 
IgG conjugated with horseradish peroxidase were 
used to detect monoclonal antibody bound to im- 
mobilized protein. o-Phenylenediamine was a 
substrate for peroxidase. The absorbance of the 
reaction products was recorded at 492 nm. 
3. RESULTS 
Fusion of splenocytes from mice immunized 
with rat aorta smooth muscle cells with mouse 
myeloma cells resulted in the establishment of 
antibody-producing hybridoma clone L8. These 
monoclonal antibodies reacted specifically with 
fibronectin (fig. 1A). The antigenic determinant for 
antibody L8 was not disturbed after incubation of 
fibronectin with 6 M urea (fig.lA). Reduction of 
fibronectin disulfide bonds by addition of 20 mM 
dithiothreitol caused the loss of the affinity an- 
tibody L8 to denatured fibronectin (fig.lA). ‘H- 
NMR spectroscopic studies of fibronectin struc- 
ture demonstrated that complete denaturation of 
the fibronectin occurred only after reduction of 
disulfide bonds [13]. In solution, containing 6 M 
urea, fibronectin undergoes only partial unfolding 
which is not accompanied by the disruption of the 
125 
V&me 217, number 1 FEBS LETTERS June 1987 
Fig.2. Effect of antifibronectin monoclonal antibody L8 on extracehular matrix formation. Human skin fibroblasts 
were cultured in medium, containing antifibronectin monoclonal antibody LB (C,D,G,G) or other antifibronectin 
monoclonaf antibodies (A,B), or preimmune mouse IgG (E,F). In (F) instead of rabbit antifibronectin polyclonal 
antibodies non-immune rabbit IgG were added. A,C,E,F,G,H, immunofhtorescence; B,D, phase contrast. 
compact structural domains [ 131. The antibody 
L&binding site seems to be a structural domain 
and disulfide bonds play an important role in 
maintaining the tertiary structure of this domain. 
We have studied the effect of monoclonal antibody 
L8 upon the organization of fibronectin in 
fibroblast culture. Fibroblasts cultured in 
fibronectin-depleted medium deposited fibronectin 
as a network of interconnecting fibrils in the ex- 
tracellular matrix (fig.2A,E). Fibroblasts cultured 
in the presence of antifibronectin antibody L8 
(0.1 mg/ml) has very little detectable fibrillar ex- 
tracellular fibronectin (fig.2C,G,H); fibronectin 
was present on the cell surface in short, fine fibrils. 
Fibroblasts plated in fibronectin-depleted medium 
containing antibody L8 attached and spread nor- 
mally on glass substrate; there were no differences 
in cell density, morphology (fig.2B,D) and 
fibronectin synthesis. To exclude the possibility 
that antibody L8 blocked immunostaining of the 
extracellular matrix with polyclona~ antifibronec- 
tin antibody we showed that binding of polyclonal 
antibody to fibronectin was not affected by an ex- 
cess of antibody L8. 
To define the position of the antibody 
L8-binding site on the fibronectin molecule we 
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have studied the effect of gelatin on binding of an- 
tibody L8 to fibronectin. The data shown in fig. 1B 
demonstrate that antibody L8 could not interact 
with fibronectin if fibronectin was bound to 
gelatin. This result suggests that the monoclonal 
antibody-binding site is located very close to the 
collagen-binding domain in the NH*-terminal part 
of the fibronectin molecule. 
4. DISCUSSION 
A monoclonal antifibronectin antibody L8 was 
obtained which inhibited the fibronectin organiza- 
tion in the fibroblast extracellular matrix. The 
epitope for these antibodies is very close to the 
collagen-binding domain of fibronectin. Thus, it 
appears that the region of fibronectin molecule 
near the collagen-binding domain plays a critical 
role in the assembly of the fibronectin extracellular 
matrix. Previously, it was demonstrated that in 
matrix assembly assay polyclonal antibody to 
whole fibronectin or specific to a 60 kDa collagen- 
binding fragment of fibronectin disrupted the 
fibronectin organization in the fibroblast ex- 
tracellular matrix [ 14,151. Recently, the presence 
of a new fibronectin cell-binding site was shown 
[8,10]. This site is located in the 70 kDa fibronec- 
tin NHz-terminal collagen-binding fragment and is 
distinct from the well-characterized cell-adhesion 
site [lo]. The 70 kDa fragment blocked incorpora- 
tion of fibronectin into the extracellular matrix 
[lo]. These data also indicate that there is a new 
matrix assembly site on fibronectin. There are two 
models explaining the incorporation of fibronectin 
into the extracellular matrix and the role of the 
new matrix assembly site in this process. The 
fibronectin may be incorporated into the ex- 
tracellular matrix via special cell-surface receptors 
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and these cell matrix assembly receptors interact 
with the fibronectin matrix assembly site [&lo]. 
Additionally to a cell-dependent mechanism of 
fibronectin fibril formation, exogenous fibronec- 
tin becomes incorporated into preexisting ex- 
tracellular matrix through a self-assembly process 
[9]. The NHz-terminal part of fibronectin, contain- 
ing the 70-60 kDa collagen-binding fragment, is 
responsible for fibronectin-fibronectin interaction 
during fibronectin fibril formation [9]. It was 
found that the gelatin-binding fragment could also 
interact with intact fibronectin, and therefore con- 
tains a site involved in fibronectin-fibronectin 
associations [16,17]. All these data suggest the 
possibility that the matrix assembly receptor for 
fibronectin is fibronectin itself. Now it is difficult 
to imagine how the interaction of fibronectin with 
the cell-surface matrix assembly receptor can lead 
to the incorporation of fibronectin into the ex- 
tracellular matrix. However, in any case a specific 
site on the fibronectin molecule is involved in 
matrix assembly and this site can be recognized by 
the monoclonal antibody L8 described here. 
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